جميع الدراسات
التوظيفالمرحلة 2تدخلي

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

This study is investigating a new medication, sotatercept, for children and teenagers aged 1 to 17 who have a specific type of pulmonary arterial hypertension (PAH). PAH is a serious condition where blood vessels in the lungs become narrow, making it hard for the heart to pump blood. The main goals are to check if sotatercept is safe for young people and how well their bodies handle the medicine over 24 weeks. Participants will continue to receive their standard PAH treatments while taking part. This is an early-stage study, meaning we are still learning about this medicine, and it's not designed to prove if the medicine works better than current treatments, but rather to understand its safety and how it behaves in children.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 2
الراعي
Merck Sharp & Dohme LLC
الهدف من التسجيل
42
ابدأ
19 يناير 2023
التاريخ المتوقع للانتهاء
21 Sep 2028

ما هو موضوع هذه الدراسة؟

This study is looking into a new medicine called sotatercept for children and teenagers between 1 and 17 years old who have a serious lung condition called pulmonary arterial hypertension. PAH happens when the blood vessels in the lungs become narrow and stiff, making it difficult for the heart to pump blood through them. This can cause the heart to work too hard.

The main reasons for this study are to see if sotatercept is safe for young people and to understand how their bodies process the medicine over 24 weeks. Participants will continue taking their usual PAH medicines during the study. This is an important step in developing new treatments for PAH in children. By understanding how sotatercept behaves in younger patients, doctors can learn more about its potential use.

It's important to know that this is a 'Phase 2' study. This means it's an early step in testing a new medicine. We're not yet trying to prove if the medicine works better than existing treatments, but rather focusing on its safety and gathering initial information on how it works in the body. This kind of research is vital for bringing new and potentially helpful medicines to those who need them.

النقاط الرئيسية

  • This study is for children aged 1-17 with a specific type of PAH.
  • It's testing a new medicine called sotatercept for safety and how the body handles it.
  • Participants will continue their usual PAH treatments.
  • This is an early-stage study (Phase 2) to gather important information.
  • Participation involves regular clinic visits for monitoring.
  • You can withdraw from the study at any time without affecting your child's care.

من قد يكون مؤهلاً؟

To join this study, a child must have a confirmed diagnosis of a specific type of pulmonary arterial hypertension (PAH), which would have been diagnosed through a special heart test called a right heart catheterisation. This diagnosis must have happened before screening for the study. The types of PAH covered include those that run in families, those caused by certain drugs, or PAH linked to other conditions like connective tissue disease.

Children need to be between 1 and 17 years old. They must also already be on a steady dose of their usual PAH medicines, such as those that relax blood vessels or help open them up. These medicines must have been taken consistently without changes for a while before the study starts.

There are also important rules about avoiding pregnancy during the study and for some time after the last dose of the study medicine, for both male and female participants. This is because we don't know the effects of the study medicine on an unborn baby. For example, specific contraception methods or agreement to not have PIV during this period would be necessary. Also, participants cannot donate blood or sperm during the study.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Is your child aged between 1 and 17 years old?
  2. Does your child have a confirmed diagnosis of a specific type of PAH?
  3. Is your child currently taking a steady dose of their usual PAH medicines?
  4. Are you able to follow specific rules about avoiding pregnancy during and after the study for your child?
  5. Has your child had their PAH diagnosis confirmed by a special heart test called a right heart catheterization?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you or your child decides to take part, they will receive the study medicine, sotatercept, for 24 weeks, while continuing all their usual PAH treatments. During this time, there will be regular visits to the clinic so the study team can monitor their health, perform necessary tests, and make sure the medicine is being taken safely. These tests might include blood samples, physical examinations, and other checks related to their heart and lungs. After the 24 weeks of treatment, there will be some follow-up visits to ensure your child is doing well and to collect final information. The exact number of visits and tests will be explained in detail by the study doctor, and the total duration of your child's involvement would be beyond the 24 weeks of treatment, including follow-up time.

المخاطر والفوائد المحتملة

Taking part in any study has potential benefits and risks. Your child might not directly benefit from taking sotatercept, as this is an early-stage study focused on safety. However, they would be helping doctors learn more about PAH and potentially contribute to new treatments for others in the future. Potential risks might include side effects from the study medicine, which would be carefully monitored by the study team. They will explain all known side effects. You are free to withdraw your child from the study at any time, for any reason, and this will not affect their regular medical care.

المواقع (35)

  • The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606)
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة· التوظيف
  • Stanford University School of Medicine ( Site 1603)
    الرمز البريدي المؤكد
    بالو ألتو، الولايات المتحدة· التوظيف
  • UCSF Benioff Children's Hospital San Francisco ( Site 1611)
    الرمز البريدي المؤكد
    سان فرانسيسكو، الولايات المتحدة· التوظيف
  • Children's Hospital Colorado ( Site 1609)
    الرمز البريدي المؤكد
    أورورا، الولايات المتحدة· التوظيف
  • Children's National Medical Center ( Site 1600)
    الرمز البريدي المؤكد
    واشنطن العاصمة، الولايات المتحدة· التوظيف
  • Cincinnati Children's Hospital Medical Center ( Site 1602)
    الرمز البريدي المؤكد
    سينسيناتي، الولايات المتحدة· التوظيف
  • Children's Hospital of Philadelphia (CHOP) ( Site 1608)
    الرمز البريدي المؤكد
    فيلادلفيا، الولايات المتحدة· التوظيف
  • Monroe Carell Jr. Children's Hospital ( Site 1601)
    الرمز البريدي المؤكد
    ناشفيل، الولايات المتحدة· مكتمل
  • Seattle Children's Hospital ( Site 1605)
    الرمز البريدي المؤكد
    سياتل، الولايات المتحدة· التوظيف
  • Children's Wisconsin ( Site 1610)
    الرمز البريدي المؤكد
    ميلووكي، الولايات المتحدة· التوظيف
  • The Children's Hospital at Westmead ( Site 0001)
    الرمز البريدي المؤكد
    ويستميد، أستراليا· التوظيف
  • Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205)
    الرمز البريدي المؤكد
    Rionegro, Colombia· التوظيف

أسئلة شائعة

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a serious lung condition where the blood vessels in the lungs become narrow, making it hard for the heart to pump blood through them.

ما هو الهدف من هذه الدراسة؟

This study aims to find out if the new medicine, sotatercept, is safe for children with PAH and how their bodies handle it over 24 weeks, alongside their usual treatments.

Will my child stop their current PAH medicines if they join?

No, your child will continue to take their usual PAH medicines during the study. Sotatercept would be an additional treatment.

What does 'Phase 2' study mean?

Phase 2 means it's an early stage of testing a new medicine. We're focusing on safety and initial understanding, not yet proving it works better than other treatments.

Can we stop participating at any time?

Yes, you can choose to withdraw your child from the study at any point, and it will not affect their medical care.

كيفية معرفة المزيد

رقم مجاني

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Study to Evaluate Sotatercept (MK-7962) in Children With Pul… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.